autologous base edited cd34+ hspcs beam-101
autologous base edited cd34+ hspcs beam-101: developed by 1 company · 1 clinical trial tracked.
autologous base edited cd34+ hspcs beam-101 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could autologous base edited cd34+ hspcs beam-101 → BEAM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Beam Therapeutics Inc. (BEAM) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial)
Primary endpoint: Change in annualized number of severe VOCs (Vascular-occlusive Crisis) relative to baseline
Frequently asked questions
Who is developing autologous base edited cd34+ hspcs beam-101?
autologous base edited cd34+ hspcs beam-101 is being developed by Beam Therapeutics Inc..
How many clinical trials involve autologous base edited cd34+ hspcs beam-101?
BioSniper tracks 1 clinical trial involving autologous base edited cd34+ hspcs beam-101.